205931-39-1

Basic information

• Product Name: 3,4-Dihydro-3-[(4-phenyl-1-piperazinyl)-methyl]-1-(2H)-naphthalenone, monohydrochloride
• Synonyms: 3,4-Dihydro-3-[(4-phenyl-1-piperazinyl)-methyl]-1-(2H)-naphthalenone, monohydrochloride
• CAS NO: 205931-39-1
• Molecular Weight: 356.895
• Mol File: 205931-39-1.mol

Chemical Properties

• CAS DataBase Reference: 3,4-Dihydro-3-[(4-phenyl-1-piperazinyl)-methyl]-1-(2H)-naphthalenone, monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-3-[(4-phenyl-1-piperazinyl)-methyl]-1-(2H)-naphthalenone, monohydrochloride(205931-39-1)
• EPA Substance Registry System: 3,4-Dihydro-3-[(4-phenyl-1-piperazinyl)-methyl]-1-(2H)-naphthalenone, monohydrochloride(205931-39-1)

Safety Data

• Hazardous Substances Data: 205931-39-1(Hazardous Substances Data)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 497-19-8 sodium carbonate 
• 108-10-1 4-methyl-2-pentanone 

Downstream Products

• 6566-40-1 4-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 

Relevant articles and documents

Inhibitors of microsomal triglyceride transfer protein and method

Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure STR1 wherein R1 to R7, Q, X and Y are as defined herein.

Nucleic acids encoding microsomal trigyceride transfer protein

Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.